Introducing a clinical trial for previously vaccinated adults Including those who are at increased risk of severe illness from COVID-19
Please take one to learn more.
Who can take part?
You may be able to take part in this study if you:
- Received a COVID-19 vaccine for the 2024-2025 season at least 6 months ago and have not received any other COVID-19 vaccine or been diagnosed with COVID-19 since this vaccination.
- Are at least 65 years of age, OR are 18-64 years of age and have at least 1 of the following medical conditions:
- Asthma
- Diabetes I or II
- Heart conditions such as previous coronary artery disease or heart failure (does not include cardiomyopathy, myocarditis, or pericarditis)
- HIV
- Mood disorder, including depression
- Parkinson’s disease
- Obesity (BMI ≥30)
- Current or former smoker
- Do not have a history of a severe reaction associated with any vaccine or vaccine component.
There will be other requirements that the study team will discuss with you.
What to expect
If this clinical trial is a good fit for you and you agree to take part, you will receive 1 dose of the study vaccine as an injection in your upper arm.
Study duration
Participation lasts for about 6 months.
Study visits
You will have at least 4 visits with the study team.
Study-related costs
There is no cost to participate in this study, and health insurance is not required. You will also be paid for completing study-related activities.
About the study vaccine
The study vaccine is a modified version of Pfizer and BioNTech’s original mRNA-based COVID-19 vaccine, which has been authorized for use in more than 149 countries. The modified formulation is designed to improve protection against Omicron LP.8.1, the COVID-19 variant recommended by the Food and Drug Administration (FDA) for the 2025-2026 respiratory virus season.
Your safety is our top priority
Before you choose to participate, you will be given all the details about the clinical trial, including potential benefits and risks. Your health will be carefully monitored throughout your time in the study.
Pursuing updated protection against COVID-19
Staying up to date on your COVID-19 vaccines is still the best way to protect yourself from experiencing severe symptoms, especially if you have certain risk factors. However, as the virus continues to change, vaccines must evolve as well. That’s why we’re developing an updated COVID-19 vaccine for the 2025-2026 respiratory virus season.
About this clinical trial
This clinical trial will help us learn if an investigational formulation of our COVID-19 vaccine is safe, and if it can help the body produce antibodies to fight off new variants of the COVID-19 virus.
Your participation in this clinical trial will contribute to the development of an updated COVID-19 vaccine that may increase protection for millions of people around the world. So, thank you for taking the time to learn more.
Tomorrow’s breakthroughs start today with you
Participation by people of all backgrounds is critical to developing vaccines that protect against COVID-19. The greater the representation among clinical trial participants, the more we can learn about potential vaccines and how they work for different people. Your participation could make a difference.
Ready to learn more?
For more information, reach out to our study team.
